Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …

Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Background Blocking the interaction between PD-1 and its ligands is a promising treatment
strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour …

Largely due to population ageing, the cancer burden from older people has been rising,
which imposed considerable pressure on current Chinese healthcare system. We provide …

Liver diseases affect millions of people worldwide. In most developed countries, the
incidence of viral hepatitis is waning as a result of modern advances in disease prevention …

Hepatitis B virus (HBV) infection is a major public health problem worldwide. The World
Health Organization (WHO) estimated that 257 million people were living with chronic HBV …

Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis,
and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured …

Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Hepatitis B virus (HBV) genotypes and subgenotypes have distinct geographical
distributions and influence a number of clinical disease features and responses to treatment …

Background & Aims There is no satisfactory way to identify patients who will maintain a
response after discontinuation of nuleos (t) ide analogue therapy for chronic hepatitis B virus …